Huang W, Shostak Y, Tarr P, Sawyers C, Carey M
Department of Biological Chemistry, Box 1737, UCLA School of Medicine, Los Angeles, California 90095, USA.
J Biol Chem. 1999 Sep 3;274(36):25756-68. doi: 10.1074/jbc.274.36.25756.
Prostate cancer is characterized by elevated serum levels of prostate-specific antigen (PSA). PSA gene expression is controlled by an androgen-responsive transcriptional enhancer. Our study suggests that formation of a nucleoprotein complex, encompassing 170 base pairs of enhancer DNA, mediates androgen-responsive PSA enhancer activity. The complex is assembled by cooperative binding of androgen receptor to at least four tandem, nonconsensus androgen response elements (AREs). Systematic mutagenesis of the AREs demonstrated that they act synergistically to stimulate androgen receptor-responsive gene expression. We discuss a mechanism whereby a combination of high androgen receptor levels in the prostate and low affinity AREs contribute to the cell type specificity and activity of the enhancer.
前列腺癌的特征是血清前列腺特异性抗原(PSA)水平升高。PSA基因表达受雄激素反应性转录增强子控制。我们的研究表明,包含170个碱基对增强子DNA的核蛋白复合物的形成介导了雄激素反应性PSA增强子活性。该复合物通过雄激素受体与至少四个串联的、非共识雄激素反应元件(AREs)的协同结合而组装。对AREs的系统诱变表明,它们协同作用以刺激雄激素受体反应性基因表达。我们讨论了一种机制,即前列腺中高雄激素受体水平和低亲和力AREs的组合促成了增强子的细胞类型特异性和活性。